Brief: Eql Pharma Reports Q1 Ebit Amounted To SEK 7.9 Mln

EQL Pharma AB

16/08/2022 19:37

Aug 16 (Reuters) - EQL Pharma AB  EQL.TE :
    * Q1 SALES IN 2022/23 AMOUNTED TO SEK 46.1 (37.3) MILLION
    * QTRLY EBIT AMOUNTED TO SEK 7.9 (3.0) MILLION, AN INCREASE
OF
163%
    * QTRLY OPERATING MARGIN WAS 17% (8%),
    * ENTERED INTO ANOTHER EXCLUSIVE OUT-LICENSING AGREEMENT
FORMELLOZAN(MELATONIN), THIS TIME WITH FRENCH COMPANY H.A.C.
PHARMA
    * DEAL IS WORTH ABOUT SEK 2 MILLION IN UPFRONT PAYMENTS AND
IN
CONNECTION WITH REGULATORY MILESTONES

Source text for Eikon:  ID:nWkr4lZ1Ty 
Further company coverage:  EQL.TE 

 ((Reuters.Brief@thomsonreuters.com;))